<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The number of prescription medications and out-of-pocket expenses of individuals with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) were evaluated to assess the economic burden of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The self-reported number of prescription medications and out-of-pocket healthcare expenses were evaluated from respondents of the United States SHIELD study with and without a diagnosis of T2DM </plain></SENT>
<SENT sid="2" pm="."><plain>Medications included monotherapy and combination therapy; combination tablets were counted as one agent </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of variance and multivariate linear regression models adjusted for age, gender, prescription insurance coverage, and household income </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of the T2DM respondents (n=3551), 40% were on 1 prescription <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent (7% insulin alone), 26% were on 2 agents, 8% were on &gt;or=3 agents, with a mean of 1.3 antidiabetic agents </plain></SENT>
<SENT sid="5" pm="."><plain>After adjusting for age, gender, insurance coverage, and income, respondents with T2DM had a significantly larger total number of prescriptions (6.2) and higher out-of-pocket expenses for both annual medical ($1158) and monthly prescription ($144) expenses, compared with respondents without T2DM (n=8686) (4.1 prescriptions, $925 annual medical, $118 monthly prescription) (p&lt;0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Increased out-of-pocket medical and medication costs in T2DM are due to the use of both <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents and other medications for treatment of comorbid conditions </plain></SENT>
</text></document>